Nova

Delaware North Continues To Grow Its Parks and Resorts Portfolio With Acquisition of Grand Canyon Squire Inn

Retrieved on: 
Monday, January 9, 2023
Park Hotels & Resorts, Great Barrier Reef, Best Western, Mather Point, Now That's What I Call Christmas!: The Signature Collection, Park, National Park Service, Kennedy Space Center, Food, Recreation, Starbucks, Acquisition, Courtyard, Nova, National Park Service rustic, Desert View Watchtower, Grand Canyon, Hotel, Risk management, Delaware North, Grand Canyon National Park, Canyon

TUSAYAN, Ariz. and BUFFALO, N.Y., Jan. 9, 2023 /PRNewswire/ -- Global hospitality and entertainment company Delaware North today announced its continued expansion in the parks and lodging sector through the acquisition of the Best Western Premier Grand Canyon Squire Inn.

Key Points: 
  • TUSAYAN, Ariz. and BUFFALO, N.Y., Jan. 9, 2023 /PRNewswire/ -- Global hospitality and entertainment company Delaware North today announced its continued expansion in the parks and lodging sector through the acquisition of the Best Western Premier Grand Canyon Squire Inn.
  • The Squire Resort is now the second hotel being operated by Delaware North near or in Grand Canyon National Park.
  • The company currently operates Yavapai Lodge, Trailer Village RV Park and several general stores in Grand Canyon Village for the National Park Service.
  • As a global leader in the hospitality and entertainment industry, Delaware North is committed to sustainability and responsible stewardship.

Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial

Retrieved on: 
Thursday, December 22, 2022
Mental Health, Health, General Health, Clinical Trials, Research, Science, Biotechnology, MEDI, Clinical trial, NOVA, KGK, Autism, Fragile X syndrome, Research, Health Canada, Phase II, NEO, Trial of the century, CSE, Science, SQ2, Psilocybin, ASD, OTC, CGMP, Nova, Therapy, Well-being, FXS, FRA, Pharmaceutical industry

“Our team at KGK has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies that move products efficiently into the global markets over the past 25 years.

Key Points: 
  • “Our team at KGK has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies that move products efficiently into the global markets over the past 25 years.
  • We are thrilled to receive approval for this pioneering Phase II A psilocybin clinical study for our client Nova Mentis,” commented Najla Guthrie, CEO of Wellbeing and KGK.
  • The trial will be led by KGK Science and recruiting efforts are expected to begin in early 2023.
  • “We are thrilled to receive Health Canada approval for our pioneering psilocybin study.

Nova to Present at the 25th Annual Needham Growth Conference

Retrieved on: 
Tuesday, January 3, 2023
Lotte New York Palace Hotel, EST, Nova, Conference

REHOVOT, Israel, Jan. 3, 2023 /PRNewswire/ -- Nova (Nasdaq: NVMI), a leading innovator and a key provider of metrology solutions for advanced process control used in semiconductor manufacturing, today announced that Dror David, Chief Financial Officer, will present at the 25th Annual Needham Growth Conference on Wednesday, January 11, 2023, at the Lotte New York Palace hotel.

Key Points: 
  • REHOVOT, Israel, Jan. 3, 2023 /PRNewswire/ -- Nova (Nasdaq: NVMI), a leading innovator and a key provider of metrology solutions for advanced process control used in semiconductor manufacturing, today announced that Dror David, Chief Financial Officer, will present at the 25th Annual Needham Growth Conference on Wednesday, January 11, 2023, at the Lotte New York Palace hotel.
  • Mr. David will be available for one-on-one in-person meetings during the two days of the conference.
  • Nova is a leading innovator and key provider of material, optical, and chemical metrology solutions for advanced process control in semiconductor manufacturing.
  • Nova delivers continuous innovation by providing state-of-the-art high-performance metrology solutions for effective process control throughout the semiconductor fabrication lifecycle.

BET99 SIGNS NEW MULTI-YEAR CANADIAN PARTNERSHIP WITH NATIONAL HOCKEY LEAGUE AND PARTNERS TO LAUNCH NHL'S NEW FREE-TO-PLAY PREDICTIVE GAME

Retrieved on: 
Tuesday, December 20, 2022
B cell, National Hockey League, YLE, Japan Professional Sports Grand Prize, Ice, ESPN, SAP, Sportsnet, TVA Sports, Ottawa Senators (senior hockey), Radio, ProSieben, Live Nation Entertainment, Sport, Partnership, UFC Hall of Fame, CF Montréal, NHL Winter Classic, Stanley, Gambling, Rogers, Montreal, Sky Sports, Playoffs, Puck, Nova, NHL Network, Religion, Montreal Alouettes, Multimedia, All rights reserved, League, Policy, Sirius XM, Stanley Cup, Business development, Education, Social media, Ottawa Senators, NHL, Prize, Gender identity, Nordic Entertainment Group, Hockey, Postmedia Network, Franco-Ontarian

BET99 will partner with the NHL to launch their new Free-to-Play game called "NHL PrePlay", and fans in Canada can access it now at www.nhl.com/NHLPrePlay .

Key Points: 
  • BET99 will partner with the NHL to launch their new Free-to-Play game called "NHL PrePlay", and fans in Canada can access it now at www.nhl.com/NHLPrePlay .
  • Each game day during the NHL season, fans will be provided a set of predictive outcome-based questions.
  • ", as well as queries using NHL Edge (Puck & Player Tracking) data, such as "Which of these players will have the hardest shot?"
  • "This partnership is groundbreaking for Canadian hockey and sports fans," said Jared Beber, CEO of BET99.

Nova Ukraine Delivers More Than $50 Million of Aid to Ukraine in 2022

Retrieved on: 
Monday, December 19, 2022
Hardship, Heat, Food, Volunteering, SAN, Hospital medicine, Nova, Nova Ukraine

SAN FRANCISCO, Dec. 19, 2022 /PRNewswire/ -- This year, Nova Ukraine provided the equivalent of $55.5 million in aid supporting the large-scale humanitarian efforts throughout Ukraine.

Key Points: 
  • SAN FRANCISCO, Dec. 19, 2022 /PRNewswire/ -- This year, Nova Ukraine provided the equivalent of $55.5 million in aid supporting the large-scale humanitarian efforts throughout Ukraine.
  • Nova Ukraine leadership reports that funds raised to date surpass $64 million, allowing humanitarian projects to continue into 2023.
  • According to Nova Ukraine co-chairman Ostap Korkuna, "since the beginning of Russia's large-scale attack on Ukraine, we've been continuously looking for effective ways to help the people of Ukraine.
  • Dedicated to providing aid to Ukraine at this time of conflict and hardship, Nova Ukraine engages a driven team of volunteers on the ground in Ukraine and the United States.

JennyCo Partners With Sequencing.com To Provide Next-Generation DNA Sequencing For Everyone

Retrieved on: 
Friday, December 9, 2022
DVD, Genome, Brandon Colby, MyHeritage, Ultimate, Partnership, Patient, Ancestry.com, DNA, Privacy, Collection, Web3, Nova, Health, SAN, Genesis, Pharmaceutical industry, Mars

Sequencing.com's DNA sequencing service analyzes between 100% of a person's genome, while their competitors, including 23andMe, AncestryDNA, and MyHeritage, analyze less than 0.1% of their genome.

Key Points: 
  • Sequencing.com's DNA sequencing service analyzes between 100% of a person's genome, while their competitors, including 23andMe, AncestryDNA, and MyHeritage, analyze less than 0.1% of their genome.
  • Dr. Brandon Colby, CEO of Sequencing.com, states, "We look forward to working with JennyCo as we bring sequencing to the world.
  • This partnership demonstrates a unique opportunity to provide state-of-the-art DNA sequencing to individuals while also allowing them to capitalize on earning rewards for their health data.
  • Sequencing.com's DNA test kits will be provided to JennyCo users through the JennyCo app, where DNA results may be deidentified and leased to healthcare institutions interested in highly-curated and unique data sets.

InsightRX to Showcase Precision Dosing Technology at ASHP 2022 Midyear Meeting

Retrieved on: 
Thursday, December 1, 2022
Antifungal, Mandalay Bay Convention Center, Doctor of Philosophy, Voriconazole, Patient, SAN, Beta-lactam, Anticoagulant, Nephrotoxicity, Literature, Pharmacokinetics, Machine learning, Risk, Patient safety, Exhibition, Health, Mortality, Magnetic resonance, Vancomycin, Toxicity, Ambiguity, BCPS, Pharmacist, Society, Senior, Tacrolimus, Nova, Doctor of Pharmacy, Precision medicine, ASHP, Infection, Pharmacy management system, Forecasting, Customer experience, AUC, Pharmaceutical industry, Medical imaging

SAN FRANCISCO, Dec. 1, 2022 /PRNewswire/ -- Today, InsightRX — which provides cloud-based precision dosing support to guide treatment decisions – announced its slate of activities and demonstrations during the American Society of Health-System Pharmacists (ASHP) 2022 Midyear Clinical Meeting and Exhibition in Las Vegas from Dec. 4-8.

Key Points: 
  • SAN FRANCISCO, Dec. 1, 2022 /PRNewswire/ -- Today, InsightRX which provides cloud-based precision dosing support to guide treatment decisions announced its slate of activities and demonstrations during the American Society of Health-System Pharmacists (ASHP) 2022 Midyear Clinical Meeting and Exhibition in Las Vegas from Dec. 4-8.
  • At ASHP Midyear, held at the Mandalay Bay Convention Center, they will be showcasing several new therapeutic categories that are now a part of their offering.
  • 2020 brought the newest vancomycin consensus guidelines ,which firmly recommended Bayesian forecasting software as the preferred method of dosing and monitoring.
  • InsightRX is a healthcare technology company that has developed a cloud-based platform for precision medicine and clinical analytics designed to individualize treatment at the point of care.

Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial

Retrieved on: 
Wednesday, November 30, 2022
Biotechnology, Alternative Medicine, FDA, Health, General Health, Pharmaceutical, Mental Health, Other Science, Research, Science, Clinical Trials, NEO, European Medicines Agency, Najla, OTC, ASD, FXS, Digital, SQ2, Food, Health Canada, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, KGK, Database, Autism, Orphan drug, CGMP, Drug development, Nova, Phases of clinical research, CTA, IIA, Digital Science, Research, Therapy, NOVA, Psilocybin, Science, CSE, Publication, Fragile X syndrome, MEDI, Trial of the century, FRA, Safety, Pharmaceutical industry

This is certainly an exciting time for KGK Science and our client Nova Mentis as we await Health Canadas review of this pioneering Phase IIa psilocybin microdose study, commented Najla Guthrie, CEO of Wellbeing Digital & KGK Science.

Key Points: 
  • This is certainly an exciting time for KGK Science and our client Nova Mentis as we await Health Canadas review of this pioneering Phase IIa psilocybin microdose study, commented Najla Guthrie, CEO of Wellbeing Digital & KGK Science.
  • The CTA is subject to a 30-day review by Health Canada, and if approval is granted, KGK intends to start the clinical study in early 2023.
  • The submission of the CTA is a significant milestone in the clinical development of Nova Mentis proprietary drug called NM-1001, said William Rascan, President & CEO of Nova Mentis.
  • Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products.

Nova LifeStyle, Inc. Reports Third Quarter FY 2022 Results

Retrieved on: 
Friday, November 18, 2022
Diamond, Perception, Nine Months, Nova, Three Months Gone, Aquaculture

LOS ANGELES, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Nova LifeStyle, Inc.(NASDAQ: NVFY) (Nova LifeStyle or the Company) today announced its financial results for the third quarter endedSeptember 30, 2022.

Key Points: 
  • LOS ANGELES, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Nova LifeStyle, Inc.(NASDAQ: NVFY) (Nova LifeStyle or the Company) today announced its financial results for the third quarter endedSeptember 30, 2022.
  • Gross profit was $1.1 million, compared toa gross profit of $1.4 million in the same period of 2021.
  • Tawny Lam, Chairperson and Chief Executive Officer ofNova LifeStyle, stated, We increased sales in the third quarter during a challenging operating environment.
  • Nova LifeStyles product lines include the Nova Brands and Diamond Sofa ( www.diamondsofa.com ).